Trials / Sponsors / Hangzhou Hanx Biopharmaceuticals, Ltd.
Hangzhou Hanx Biopharmaceuticals, Ltd.
Industry · 6 registered clinical trials — 3 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours Biliary Tract Cancer, Melanoma | Phase 1 / Phase 2 | 2025-01-17 |
| Recruiting | A Phase 2 Study of HX301 in Patients with High-grade Giloma Glioma | Phase 1 / Phase 2 | 2025-01-08 |
| Recruiting | Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma Relapsed/Refractory Lymphoma | Phase 1 / Phase 2 | 2021-12-31 |
| Completed | Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Soli Advanced Solid Tumor | Phase 2 | 2021-05-12 |
| Completed | The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2020-09-15 |
| Active Not Recruiting | Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2020-05-28 |